Yes, recommend reporting is coupled with a recommendation that SDH IHC is performed and the finding is considered to be a non-actionable secondary finding unless there is immunohistochemical evidence of SDHB/SDHA loss in the tumour or a family history of SDHA-associated tumours†. The gene discussed is SDHA; the disease is neoplasm.